Damelin et al. developed a PTK7-targeted antibody-drug conjugate (PTK7-ADC), and treatment with PTK7-ADC depleted tumor-initiating cells and induced tumor regression in TNBC patient tissue-derived or TNBC cell line-derived xenografts [86]. The gene discussed is PTK7; the disease is neoplasm.